ALT Altimmune Inc

Altimmune Statement on the Passing of Dr. Stephen Harrison

Altimmune Statement on the Passing of Dr. Stephen Harrison

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing.

Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.

Contact:

Rich Eisenstadt

Chief Financial Officer

Phone: 240-654-1450



EN
25/04/2024

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Closing of $75 Million Registered Direct Offering ...

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. Th...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Pricing of $75 Million Registered Direct Offering ...

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross procee...

January 28, 2026 1 EN
Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc bought 5,000 shares at 4.082USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

01/09/26 January 9, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutid...

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of pa...

January 5, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces that Pemvidutide Achieved Key Measures of Success ...

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced ...

December 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch